Biotin and Other Interferences in Immunoassays

Amitava Dasgupta received his Ph. D in chemistry from Stanford University and completed his fellowship training in Clinical Chemistry from the Department of Laboratory Medicine at the University of Washington School of Medicine at Seattle. He is board certified in both Toxicology and Clinical Chemistry by the American Board of Clinical Chemistry. Currently, he is a tenured Full Professor of Pathology and Laboratory Medicine at the University of Kansas Medical Center and Director of Clinical Laboratories at the University of Kansas Hospital. Prior to this appointment he was a tenured Professor of Pathology and Laboratory Medicine at the University of Texas McGovern medical School from February 1998 to April 2022. He has 252 papers to his credit. He is in the editorial board of four journals including Therapeutic Drug Monitoring, Clinica Chimica Acta, Archives of Pathology and Laboratory Medicine, and Journal of Clinical Laboratory Analysis.

• 1. Immunoassay design and mechanism of biotin interference2. Biotin: Pharmacology, Pathophysiology and Assessment of Biotin Status3. Biotin: From Supplement to Therapy4. Effect of Biotin on Clinical Laboratory Test Results: How to Avoid such Interferences?5. Issues of Interferences in Clinical Chemistry Tests including Heterophilic Antibody Interferences6. Issues of Interferences in Therapeutic Drug Monitoring7. Issues of Interference in Drugs of Abuse Testing and Toxicology